CAS: 1809068-70-9
Marchio | Dati del prodotto | Purezza | Fascia di prezzo | Consegna prevista |
---|---|---|---|---|
N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide REF: 3D-JXC06870CAS: 1809068-70-9 | Min. 95% | 453,00 €~4.405,00 € | Ven 27 Dic 24 | |
SMAP-2 REF: TM-T12934CAS: 1809068-70-9 | 98% | Prezzo su richiesta | Ven 03 Gen 25 |
N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide
CAS:1809068-70-9
Please enquire for more information about N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide including the price, delivery time and more detailed …
Formula:
C27H27F3N2O4S
Purezza:
Min. 95%
Peso molecolare:
532.6 g/mol
Ref: 3D-JXC06870
1mg | 453,00 € | ||
2mg | 711,00 € | ||
5mg | 1.276,00 € | ||
10mg | 1.855,00 € | ||
25mg | 4.405,00 € |
Consegna stimata in Stati Uniti, il Venerdì 27 Dicembre 2024
SMAP-2
CAS:1809068-70-9
SMAP-2: oral PP2A activator, targets Aα subunit, halts KRAS-mutant lung cancer growth.
Formula:
C27H27F3N2O4S
Purezza:
98%
Colore e forma:
Solid
Peso molecolare:
532.57
Ref: TM-T12934
25mg | 1.410,00 € | ||
50mg | 1.845,00 € | ||
100mg | 2.329,00 € |
Consegna stimata in Stati Uniti, il Venerdì 03 Gennaio 2025